clinical trial

Is anyone in rolled or thinking about trail in gene therapy CERE 120

[Jeni]

I have never heard of it Anthony???? Where did you find this one???

[Hidden in reply to Jeni]

This is being offered at Rush in Chicago

[Hidden]

Ceregene Inc., a biotechnology company developing treatments for neurodegenerative diseases such as Parkinson's disease, will present new data demonstrating long-term, biologically-active expression of neurturin, a nervous system growth factor delivered to the degenerating dopamine nerves in patients with Parkinson's disease following treatment with CERE-120 (AAV2-neurturin).  Raymond T. Bartus, Ph.D., Ceregene's chief scientific officer and executive vice president, was invited to give a presentation entitled "The Development of AAV2-neurturin (CERE-120) for Parkinson's Disease: A Review of the Challenges and Translation Issues Confronted During the Course of Establishing 'Clinical Proof of Concept,'" at the annual meeting of the American Society for Gene and Cell Therapy during the Clinical Trials I Symposium on Thursday, May 17, 2012 in Philadelphia, PA.  CERE-120 is a viral vector engineered to deliver the nervous system growth factor neurturin (NRTN), which has the ability to rejuvenate degenerating dopamine-producing neurons, restoring function and keeping them alive.  NRTN has been shown to safely protect and restore damaged nigrostriatal nerves in animal models of Parkinson's disease and appears safe in humans tested in four Ceregene-sponsored clinical studies enrolling a total of 120 patients, 80 of whom were administered CERE-120.  A previous double blind-controlled human study demonstrated clinical benefit on several motor and Quality of Life (QOL) endpoints 12 and 18 months following CERE-120 delivery (with no measure favoring sham) and established clinical proof of concept in humans. 

Continued on Next page >>

Posted in: Drug Trial News | Medical Condition News

Tags: Alzheimer's Disease, Biotechnology, Brain, Cell, Dopamine, Gene, Nervous System, Parkinson's Disease, Protein, Putamen, Viral Vector, Virus

[Jeni]

Thanks, so how do we sign up for it?

[Hidden in reply to Jeni]

Rush Hospital Chicago

[Jeni]

I actually found the email for it and requested to be in the study. Thanks....

[Hidden in reply to Jeni]

Good luck I wanted to in this one but can't .

[Jeni]

Why can't you? They had 3 or 4 different ones...

[Hidden in reply to Jeni]

I had surgery in September of 2011 in Boston using GAD gene therapy.